Bevacizumab versus Ranibizumab on As-Needed Treatment Regimen for Neovascular Age-Related Macular Degeneration in Turkish Patients
Figure 1
The changes in mean visual acuity in the bevacizumab group and ranibizumab groups. The graph shows the mean LogMAR visual acuity levels from baseline to the most recent followup. The change in mean best corrected visual acuity from the baseline to months 3, 6, 9, 12, and the last visit (Last) was not statistically different between the two groups ( for all).
